Imetelstat (GRN163L)--telomerase-based cancer therapy

Röth, Alexander; Harley, Calvin B; Baerlocher, Gabriela M (2010). Imetelstat (GRN163L)--telomerase-based cancer therapy. Recent results in cancer research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, 184, pp. 221-234. Berlin: Springer 10.1007/978-3-642-01222-8_16

Full text not available from this repository. (Request a copy)

Telomeres and telomerase play essential roles in the regulation of the lifespan of human cells. While normal human somatic cells do not or only transiently express telomerase and therefore shorten their telomeres with each cell division, most human cancer cells typically express high levels of telomerase and show unlimited cell proliferation. High telomerase expression allows cells to proliferate and expand long-term and therefore supports tumor growth. Owing to the high expression and its role, telomerase has become an attractive diagnostic and therapeutic cancer target. Imetelstat (GRN163L) is a potent and specific telomerase inhibitor and so far the only drug of its class in clinical trials. Here, we report on the structure and the mechanism of action of imetelstat as well as about the preclinical and clinical data and future prospects using imetelstat in cancer therapy.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Baerlocher, Gabriela M.

ISSN:

0080-0015

Publisher:

Springer

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:08

Last Modified:

08 Jun 2016 10:20

Publisher DOI:

10.1007/978-3-642-01222-8_16

PubMed ID:

20072842

Web of Science ID:

000273346300016

URI:

https://boris.unibe.ch/id/eprint/670 (FactScience: 200341)

Actions (login required)

Edit item Edit item
Provide Feedback